Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TherapeuticsMD Inc
TXMD | US
1.57
USD-0.03
-1.56%
TXMD | US
About TherapeuticsMD Inc
Sector
Healthcare
Industry
Drug Manufacturers - Major
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.57
Open
1.62
High
1.62
Low
1.56
TherapeuticsMD Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXYBIJUVA and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD Inc. was founded in 2008 and is headquartered in Boca Raton Florida.
View LessTXMD | US
Risk
31.4
Sharpe
-0.72
Luna's Score
40/100
Recommendation
Sell
Luna says (TXMD | US)
What's Working
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
32.6%1 month
31.4%3 months
45.3%6 months
48.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
2.29
Price to book
0.67
Debt to equity
0.27
Debt to assets
0.19
Ent. to EBITDA
14.81
Ent. to rev.
20.90
PEG
-0.73
Other Fundamentals
EBITDA
-5.43M
MarketCap
18.16M
MarketCap(USD)
18.16M
Div. yield
-
Op. margin
-503.85
Erngs. growth
-
Rev. growth
-46.50
Ret. on equity
-16.42
Short ratio
2.13
Short perc.
0.30
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.19
Range1M
0.19
Range3M
0.44
Volumes: Market Activity
Rel. volume
0.76
Price X volume
16.12K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 14.81 | 21.06 | Cheaper |
| Ent. to Revenue | 20.90 | 5.64 | Expensive |
| PE Ratio | - | 41.17 | - |
| Price to Book | 0.67 | 11.46 | Cheaper |
| Dividend Yield | - | 3.27 | - |
| Std. Deviation (3M) | 45.27 | 39.12 | Par |
| Debt to Equity | 0.27 | 1.72 | Cheaper |
| Debt to Assets | 0.19 | 0.31 | Cheaper |
| Market Cap | 18.16M | 200.67B | Emerging |
